---
schema_version: "secwatch.filing_event.v1"
accession: "0001420800-24-000019"
form_type: "8-K"
ticker: "ENOV"
cik: "0001420800"
company_name: "Enovis CORP"
filed_at: "2024-08-07T23:59:59+00:00"
generated_at: "2026-05-31T11:41:17.016651+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Enovis Q2 sales up 23% to $525M; raises adjusted EPS guidance to $2.62-$2.77

## Summary
- Q2 net sales $525M (+23% reported, +5% comparable); Recon sales +60% reported.
- Reported net loss from cont ops $0.34/sh; adjusted EPS $0.62; adj EBITDA $90M (17.2% of sales, +190bps).
- Raised FY2024 adj EPS guidance to $2.62-$2.77 (from $2.52-$2.67); revenue narrowed to $2.08-$2.13B.
- Received FDA 510k clearance for Arvis 2.0 Shoulder and Altivate Reverse Glenoid; launches expected Q3 2024.
- Opened new manufacturing facility in San Daniele and Business Technology Center in Lisbon.

## SEC filing metadata
- accession: 0001420800-24-000019
- form_type: 8-K
- ticker: ENOV
- cik: 0001420800
- company_name: Enovis CORP
- filed_at: 2024-08-07T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1420800/000142080024000019/0001420800-24-000019-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1420800/000142080024000019/cfx-20240807.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001420800-24-000019
- JSON: https://secwatch.observer/filing/0001420800-24-000019.json
- Plain text: https://secwatch.observer/filing/0001420800-24-000019.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.